Project Details
Description
A Phase I Study to Evaluate The Safety and Tolerability of Tandemly-Purified Allogeneic CD34+CD90+ HSC Administered Following Conditioning with AMG 191 to Achieve Engraftment and Immune Reconstitution in Patients with SCID
| Status | Active |
|---|---|
| Effective start/end date | 5/1/20 → 4/30/25 |
Funding
- JASPER THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.